Browsing by Subject "Gelsolin"

Sort by: Order: Results:

Now showing items 1-3 of 3
  • Schmidt, Eeva-Kaisa; Mustonen, Tuuli; Kiuru-Enari, Sari; Kivelä, Tero T.; Atula, Sari (2020)
    Background Hereditary gelsolin (AGel) amyloidosis is an autosomal dominantly inherited systemic amyloidosis that manifests with the characteristic triad of progressive ophthalmological, neurological and dermatological signs and symptoms. The National Finnish Gelsolin Amyloidosis Registry (FIN-GAR) was founded in 2013 to collect clinical data on patients with AGel amyloidosis, including altogether approximately one third of the Finnish patients. We aim to deepen knowledge on the disease burden and life span of the patients using data from the updated FIN-GAR registry. We sent an updated questionnaire concerning the symptoms and signs, symptomatic treatments and subjective perception on disease progression to 240 members of the Finnish Amyloidosis Association (SAMY). We analyzed the lifespan of 478 patients using the relative survival (RS) framework. Results The updated FIN-GAR registry includes 261 patients. Symptoms and signs corresponding to the classical triad of ophthalmological (dry eyes in 93%; corneal lattice amyloidosis in 89%), neurological (numbness, tingling and other paresthesias in 75%; facial paresis in 67%), and dermatological (drooping eyelids in 86%; cutis laxa in 84%) manifestations were highly prevalent. Cardiac arrhythmias were reported by 15% of the patients and 5% had a cardiac pacemaker installed. Proteinuria was reported by 13% and renal failure by 5% of the patients. A total of 65% of the patients had undergone a skin or soft tissue surgery, 26% carpal tunnel surgery and 24% at least unilateral cataract surgery. As regards life span, relative survival estimates exceeded 1 for males and females until the age group of 70-74 years, for which it was 0.96. Conclusions AGel amyloidosis causes a wide variety of ophthalmological, neurological, cutaneous, and oral symptoms that together with repeated surgeries cause a clinically significant disease burden. Severe renal and cardiac manifestations are rare as compared to other systemic amyloidoses, explaining in part the finding that AGel amyloidosis does not shorten the life span of the patients at least for the first 75 years.
  • Schmidt, Eeva-Kaisa; Mustonen, Tuuli; Kiuru-Enari, Sari; Kivelä, Tero T; Atula, Sari (BioMed Central, 2020)
    Abstract Background Hereditary gelsolin (AGel) amyloidosis is an autosomal dominantly inherited systemic amyloidosis that manifests with the characteristic triad of progressive ophthalmological, neurological and dermatological signs and symptoms. The National Finnish Gelsolin Amyloidosis Registry (FIN-GAR) was founded in 2013 to collect clinical data on patients with AGel amyloidosis, including altogether approximately one third of the Finnish patients. We aim to deepen knowledge on the disease burden and life span of the patients using data from the updated FIN-GAR registry. We sent an updated questionnaire concerning the symptoms and signs, symptomatic treatments and subjective perception on disease progression to 240 members of the Finnish Amyloidosis Association (SAMY). We analyzed the lifespan of 478 patients using the relative survival (RS) framework. Results The updated FIN-GAR registry includes 261 patients. Symptoms and signs corresponding to the classical triad of ophthalmological (dry eyes in 93%; corneal lattice amyloidosis in 89%), neurological (numbness, tingling and other paresthesias in 75%; facial paresis in 67%), and dermatological (drooping eyelids in 86%; cutis laxa in 84%) manifestations were highly prevalent. Cardiac arrhythmias were reported by 15% of the patients and 5% had a cardiac pacemaker installed. Proteinuria was reported by 13% and renal failure by 5% of the patients. A total of 65% of the patients had undergone a skin or soft tissue surgery, 26% carpal tunnel surgery and 24% at least unilateral cataract surgery. As regards life span, relative survival estimates exceeded 1 for males and females until the age group of 70–74 years, for which it was 0.96. Conclusions AGel amyloidosis causes a wide variety of ophthalmological, neurological, cutaneous, and oral symptoms that together with repeated surgeries cause a clinically significant disease burden. Severe renal and cardiac manifestations are rare as compared to other systemic amyloidoses, explaining in part the finding that AGel amyloidosis does not shorten the life span of the patients at least for the first 75 years.
  • Kyyrönen, Marika (Helsingfors universitet, 2010)
    Suomalaisen perinnöllisen gelsoliiniamyloidoosin syntymekanismit ovat vielä epäselviä. Tässä tutkimuksessa pyrittiin selvittämään, mitkä muut syyt voisivat johtaa gelsoliiniamyloidoosissa ilmenevien oireiden syntyyn amyloidisäikeiden muodostumisen lisäksi. Potilaasta eristettyjä sileälihassoluja kasvatettiin ja niistä eristettiin proteiinit. Näiden solujen proteiiniekspressiota verrattiin kontrollisileälihassolujen proteiiniekspressioon. Ekspressio erot selvitettiin SDS-PAGE-analyysillä ja Coomassie-värjäyksellä sekä anti-FAF-, alfa-aktiini- ja beeta-aktiini-vasta-ainevärjäyksillä. Proteiinit tunnistettiin massaspektrometrillä. Tässä tutkimuksessa tunnistetut kaikki viisi proteiinia (alfa-aktiini, anneksiini A1, anneksiini A2, anneksiini V ja vimentiini), joiden ekspressiot erosivat gelsoliiniamyloidoosia sairastavan potilaan- ja kontrolli-sileälihassolujen välillä, ovat yhteyksissä solun tukirankaan ja erityisesti aktiinisäikeiden muokkaukseen. Lisäksi solut värjätiin alfa-aktiinivasta-aineella. Aktiinitukiranka oli rikkonainen verrattuna kontrollisolujen aktiinitukirankaan. Tämän tutkimuksen perusteella voidaan siis olettaa gelsoliiniamyloidoosin oireiden johtuvan amyloidin kertymisen lisäksi viallisesta aktiinitukirangan homeostasiasta. Amyloidin muodostuminen on kuitenkin yksi tärkeimmistä oireiden syistä. Koska gelsoliiniamyloidoosiin ei ole vielä olemassa spesifistä hoitoa, olisi sellainen tärkeää löytää. Siksi tässä tutkimuksessa selvitettiin ryhmämme kehittämän amyloidi-inhibiittori kykyä estää amyloidisäikeiden muodostuminen Tioflaviini-T-mittauksilla (ThT). Inhibiittori osoittautui tehokkaaksi amyloidisäikeiden muodostumisen estäjäksi. Amyloidi-inhibiittori voisikin olla tulevaisuudessa lääke gelsoliiniamyloidoosiin.